- Details
- Description
-
Packaging Size90t/bottle
-
Strength180mg
-
CompositonBempedoic acid
-
TreatmentHypercholesterolemia
-
FormTable
-
BrandLuciBemp
-
Quantity Unit180mg*90t/box
-
ManufacturerLucius Pharmaceuticals (Lao) Co.,Ltd
About Bempedoic acid
Bempedoic acid is an oral, once-daily non-statin medication approved to treat high cholesterol (primary hyperlipidemia) and reduce cardiovascular risk, particularly in patients who cannot tolerate statins. It reduces LDL cholesterol by inhibiting ATP citrate lyase (ACL) in the liver. Common side effects include hyperuricemia (high uric acid), gout, tendon rupture, and potential liver enzyme elevation.
Primary Hyperlipidemia
Indicated as an adjunct to diet and exercise, in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH)
180 mg PO daily
Major Adverse Cardiovascular Events (MACE)
Indicated to reduce risk of MACE (cardiovascular death, myocardial infarction, stroke, or coronary revascularization) in adults at increased risk for these events who are unable to take recommended statin therapy (including those not taking a statin)
180 mg PO daily
Dosage Modifications
Renal impairment
- Mild, moderate, severe, or renal failure: No dosage adjustment required
Hepatic impairment
- Mild or moderate (Child-Pugh A or B): No dosage adjustment required
- Severe (Child-Pugh C): Not studied
Dosing Considerations
Monitoring: After initiating, analyze lipid levels within 8-12 weeks
